Levels of C-Reactive Protein Associated with High and Very High Cardiovascular Risk Are Prevalent in Patients with Rheumatoid Arthritis by Graf, Jonathan et al.
Levels of C-Reactive Protein Associated with High and
Very High Cardiovascular Risk Are Prevalent in Patients
with Rheumatoid Arthritis
Jonathan Graf
1,2, Rebecca Scherzer
1,3, Carl Grunfeld
1,3, John Imboden
1,2*
1Department of Medicine, University of California San Francisco, San Francisco, California, United States of America, 2Division of Rheumatology, San Francisco General
Hospital, San Francisco, California, United States of America, 3Division of Endocrinology and Metabolism, San Francisco VA Medical Center, San Francisco, California,
United States of America
Abstract
Objective: C-reactive protein (CRP) levels.3 mg/L and.10 mg/L are associated with high and very high cardiovascular risk,
respectively, in the general population. Because rheumatoid arthritis (RA) confers excess cardiovascular mortality, we
determined the prevalence of these CRP levels among RA patients stratified on the basis of their RA disease activity.
Methods: We evaluated physician and patient global assessments of disease activity, tender and swollen 28 joint counts,
erythrocytesedimentation rate (ESR), and CRP measured in a single clinic visit for 151 RA patients. Disease activity was calculated
using the Clinical Disease Activity Index (CDAI) and the Disease Activity Score 28 Joints (DAS28-ESR and DAS28-CRP).
Results: Median CRP level was 5.3 mg/L. 68% of patients had CRP.3 mg/L, and 25% had CRP.10 mg/L. Of those with 0–1
swollen joints (n=56), or 0–1 tender joints (n=81), 64% and 67%, respectively, had CRP.3 mg/L, and 23% and 20%,
respectively, had CRP.10 mg/L. Of those with remission or mildly active disease by CDAI (n=58), DAS28-ESR (n=39), or
DAS28-CRP (n=70), 49–66% had CRP.3 mg/L, and 10–14% had CRP.10 mg/L. Of patients with moderate disease activity
by CDAI (n=51), DAS28-ESR (n=78), or DAS28-CRP (n=66), 67–73% had CRP.3 mg/L, and 25–33% had CRP.10 mg/L.
Conclusion: Even among RA patients whose disease is judged to be controlled by joint counts or standardized disease
scores, a substantial proportion have CRP levels that are associated high or very high risk for future cardiovascular events in
the general population.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
whose predominant clinical manifestations are synovitis and
progressive articular damage. Patients with RA, however, experi-
ence excess cardiovascular morbidity and mortality that are not
explained by Framingham cardiac risk factors but that have been
linked to chronic systemic inflammation [1–7]. To date, C-reactive
protein (CRP), a sensitive indicator of systemic inflammation, is the
best biomarker for the excess cardiovascular disease associated with
RA. Serum levels of CRP are independent predictors for preclinical
cardiovascular disease (CVD), cardiovascular events, and overall
cardiovascular mortality in RA patients [8–13]. CRP independently
correlates with preclinical atherosclerotic disease in RA patients, as
assessed by measurements ofcarotidintimamedia thickness, carotid
plaque, coronary calcification, aortic pulse wave velocity, and
endothelial cell dysfunction [10–15].
A substantial body of evidence also implicates systemic
inflammation in the pathogenesis of atherosclerosis and CVD in
the general population [16]. Elevated serum levels of CRP
independently predict future cardiovascular events and preclinical
CVD in the general population [17–21]. In a joint scientific
statement, the American Heart Association (AHA) and Centers for
Disease Control (CDC) categorized individuals whose CRP levels
are.3 mg/L as being at high risk for future CVD events, citing
their two-fold increased risk compared to those with a baseline
CRP,1 mg/L [22]. However, the relationship between CRP and
cardiovascular events is linear, not dichotomous [23]. Thus,
individuals with CRP levels in the 1–3 mg/L range have an
elevated risk of future cardiovascular events when compared to
patients whose CRP is,0.5 mg/L [23]. At the other end of the
spectrum, those with CRP.10 mg/L are at greater risk than those
with CRP levels of 3 to 10 mg/L and are considered to be at very
high risk of future cardiovascular events [23].
Serum CRP levels in RA patients frequently are above the
3 mg/L and 10 mg/L cutoffs associated with high and very high
risk for CVD in the general population. For example, cross-
sectional data from a recent observational cohort of 767 RA
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that.50% of those RA patients had CRP levels associated with
very high cardiovascular risk [24]. For comparison, less than 5% of
individuals in the Women’s Health Study had CRP le-
vels.10 mg/L [17,23].
Current therapeutic regimens can improve or suppress articular
manifestations in many RA patients [25]. It is not known, however,
whether control of articular disease is associated with effective
suppression of the systemic inflammation that has been linked to
excess CVD in RA. Accordingly, we performed a cross-sectional
analysis of a cohort of RA patients in order to determine whether
CRP levels that are associated with high or very high cardiovascular
risk are prevalent in patients whose articular disease is controlled.
Because there is no single uniformly accepted measure of RA
disease activity, we judged successful control using each of the
following: the physician global assessment of disease activity, the
patient global assessment of disease activity, the number of swollen
joints, the number of tender joints, and two standardized
assessments of RA activity: the Clinical Disease Activity Index
(CDAI) and the Disease Activity Score-28 joints (DAS28).
Materials and Methods
Patients
The 151 patients in this study were enrolled from the RA clinic at
San Francisco General Hospital and are part of the University of
California San Francisco (UCSF) RA cohort. All patients met ACR
1987 classification criteria for RA and had their therapeutic
regimens determined by a UCSF-affiliated rheumatologist. For this
study, we included all enrollees who had tender and swollen 28 joint
counts, a patient global assessment of disease activity, erythrocyte
sedimentation rate (ESR), and CRP determined during a single
clinic visit between October, 2006 and April, 2008. Data were
extracted from the most recent clinical encounter in which these
criteria were met. 145 patients also had a physician’s global
assessment recorded at that encounter. This study was approved by
the UCSF Committee on Human Research, and all patients signed
consent documents allowing their clinical information to be
gathered and analyzed for research purposes.
Clinical Assessments
Data regarding patient age, gender, self-reported ethnicity,
disease duration, seropositivity, medication use, and radiographic
changes were extracted from each patient’s clinical record. Four
UCSF faculty rheumatologists trained in the DAS evaluation
performed the tender and swollen joint counts and physician
global assessment. Swollen and tender joint counts were analyzed
categorically as: 0 joint, 1 joint, 2–4 joints, and 5+ joints. Patient
and physician global assessments of disease activity were recorded
independently using a standard 100 mm horizontal visual analog
scale in which 0=no activity and 100=maximal activity [26]. The
Clinical Disease Activity Index (CDAI), a validated measure of
disease activity that does not incorporate biomarkers of inflam-
mation, was calculated using swollen and tender joint counts and
the physician and patient global assessments [24]. Because 6
patients did not have a physician global assessment recorded, 145
patients were analyzed using the CDAI. CDAI was categorized as
remission (0–2.8) or mild (.2.8 to 10), moderate (.10 to 22), and
severe activity (.22) using published cut points [27]. In contrast to
the CDAI, the DAS28 quantifies RA disease activity using a
formula that includes a measure of systemic inflammation, either
ESR (DAS28-ESR) or CRP (DAS28-CRP), as well as the patient
global assessment and the tender and swollen joint counts [28].
The DAS28-ESR and DAS28-CRP were analyzed using the
published cut points for remission (#2.6) or mild (.2.6 to 3.2),
moderate (.3.2 to 5.1), and severe activity (.5.1) [29].
Laboratory Measurements
All laboratory specimens were collected at the time of the clinic
visit, with testing conducted in the San Francisco General Hospital
clinical laboratories. ESR was measured according to standard
Westergren techniques. High sensitivity CRP was measured in
serum that had been frozen and stored at 220uC for less than 4
days. CRP assays were performed with a Beckman Coulter
IMMAGE Nephelometry System (Fullerton, CA), using a near-
infrared particle immunoassay, with a laser diode at 940 nm, a
detection limit of 0.20 mg/L, and a measuring range of 0.20–
1440 mg/Liter.
Statistics
Spearman correlation coefficients were calculated to examine
the associations of clinical characteristics, joint counts and CRP,
since many measures were found to be non-normally distributed.
The prevalence of elevated CRP was compared across ordered
joint, DAS28, and CDAI categories using the Cochran-Armitage
test for trend [30]. Elevated CRP levels were defined as.3 mg/L
and 10 mg/L, levels associated with high and very high risk,
respectively, of future cardiovascular events in the general
population [23]. Median CRP levels were compared across
categories using the non-parametric Jonckheere-Terpstra test
[31]. All analyses were conducted using the SAS system, version
9.1 (SAS Institute, Inc., Cary, NC).
Results
Demographics and disease characteristics
The mean age of the patients was 52.4 years old, and the mean
duration of RA was 9.9 years (Table 1). 89% of patients were
female, a slightly higher prevalence of women than is typically
reported, and, unlike most cohorts of RA in the United States, the
majority was of Hispanic or Asian origin (Table 1). 84% and 82%
of the study population were positive for rheumatoid factor and
anti-cyclic citrullinated peptide (anti-CCP) antibodies, respectively
(Table 1). 70% of patients had either joint space narrowing or
erosive changes identified on radiographs of the hands or feet
(Table 1).
Disease activity in this patient population
The median physician global assessment of disease activity was
27, and the median patient global assessment was 47 (Table 1).
The median numbers of swollen and tender joints in this
population of RA patients were 2 and 1, respectively, out of a
total possible joint count of 28 (Table 1). The median DAS28-ESR
and DAS28-CRP were 3.9 and 3.3, respectively (Table 1). The
median CDAI was 12.5 (Table 1). Median ESR was above normal
(ESR 29 mm/h vs.#20 mm/h). Median and mean CRP levels
were 5.3 mg/L and 11.4 mg/L, respectively.
CRP levels associated with high cardiovascular risk in
patients with low disease activity as measured by
physician or patient global assessments
Sixty-eight percent of study patients had CRP levels.3 mg/L
(Table 1). Because over two-thirds of our patients had CRP levels
associated with high cardiovascular risk [22,23], we examined
CRP levels in relation to clinical assessments of disease activity. A
majority of those patients who were judged by their physicians to
have mild disease activity (defined as a physician global assessment
CRP in Rheumatoid Arthritis
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(50 out of 79=63%). Indeed, the prevalence of CRP.3 mg/L
was similar to that in the patients judged to have moderate or
severe disease by physician global assessment of$30 (46 out of
66=74%, p=0.21), and the overall correlation of the physician
global assessment of disease activity with CRP was weak (r=0.20,
p=0.014, Figure 1a).
Likewise, a substantial majority of those patients with self-rated
low disease activity (scores of less than 30 out of 100), had
CRP.3 mg/L (29 out of 41=71%) which was similar to those
with a patient global assessment of$30 (74 out 110=67%,
p=0.84). The patient global assessment of disease activity had a
weak, although still statistically significant, overall correlation with
CRP (r=0.19, p=0.022, Figure 1b).
CRP levels in patients with minimal clinical joint findings
The low median number of affected joints (Table 1) indicated
that a substantial proportion of patients in the study had little or
no clinically detectable synovitis. Indeed, 39 patients had no
swollen joints, while another 17 had only one swollen joint
(Figure 2a). Despite little clinical evidence of articular disease in
these two groups, 59% of those with no swollen joints, and 76%
with only 1 swollen joint, had CRP levels.3 mg/L (Figure 2a).
Table 1. Subject Demographics and Clinical Characteristics.
Parameter Statistic
N1 5 1
Age (y) Median (IQR) 53.0 (45.0–62.0)
Mean6SD 52.4613.6
RA Disease Duration Median (IQR) 7.9 (3.8–12.3)
Mean6SD 9.968.5
Gender Female 135 (89%)
Ethnicity Asian/Pacific Islander 50 (33%)
Black/African American 16 (11%)
Latino/Hispanic 73 (48%)
White/Caucasian 9 (6%)
Other 3 (2%)
Rheumatoid Factor n (%) 127 (84%)
Anti-CCP Positive n (%) 118 (82%)
Radiographic Changes n (%) 105 (70%)
Physician Global Median (IQR) 27.0 (17.0–45.0)
Assessment Mean6SD 31.2619.4
Patient Global Median (IQR) 47.0 (28.0–64.0)
Assessment Mean6SD 47.4622.7
Swollen Joint Count Median (IQR) 2.0 (0.0–7.0)
Mean6SD 4.765.6
Tender Joint Count Median (IQR) 1.0 (0.0–4.0)
Mean6SD 3.365.1
DAS28-ESR Median (IQR) 3.9 (3.2–5.0)
Mean6SD 4.161.4
DAS28-CRP Median (IQR) 3.3 (2.6–4.3)
Mean6SD 3.561.2
CDAI Median (IQR) 12.5 (7.9–22.0)
Mean6SD 15.8611.4
ESR (mm/hr) Median (IQR) 29.0 (14.0–45.0)
Mean6SD 32.3623.9
CRP (mg/L) Median (IQR) 5.3 (2.2–9.9)
Mean6SD 11.4621.1
n( % ) .3 mg/L 103 (68%)
n( % ) .10 mg/L 37 (25%)
DMARD use n (%) 124 (82%)
Biologic use n (%) 41 (27%)
Anti-CCP, antibodies to cyclic citrullinated peptides.
DAS28, disease activity score 28 joints.
CDAI, clinical disease activity index.
DMARD, synthetic disease modifying antirheumatic drug.
doi:10.1371/journal.pone.0006242.t001
Figure 1. Scatterplots of CRP Levels by (a) Physician and (b)
Patient Global Assessments of Disease Activity. CRP (log2) levels
and global assessments were determined at the same clinic visit. The
global assessments were recorded independently using a 100 mm
visual analog scale in which 0=no disease activity and 100=maximal
disease activity. The dotted reference lines denote a global assessment
of 30 and CRP=3 mg/L. CRP levels.3 mg/L are associated with high
cardiovascular risk in the general population according to a scientific
statement from the AHA and the CDC (7).
doi:10.1371/journal.pone.0006242.g001
CRP in Rheumatoid Arthritis
PLoS ONE | www.plosone.org 3 July 2009 | Volume 4 | Issue 7 | e6242The prevalence of CRP.3 mg/L in those with 0, 1, 2–4, or 5+
swollen joints was similar (p=0.38), and there was little trend
toward increasing CRP levels (p=0.19). CRP did not correlate
significantly with the swollen joint count overall (r=0.13,
p=0.12).
Similar results were observed when the tender joint count was
used to assess articular disease. 66% of patients with no tender
joints (n=58) and 70% of those with 1 tender joint (n=23) had
CRP levels.3 mg/L (Figure 2b). The median CRP levels in these
2 groups were elevated at 5.2 and 7.7 mg/L, respectively. The
prevalence of elevated CRP levels remained similar across all
tender joint categories (p=0.61 across all categories). CRP did not
correlate significantly with the tender joint count overall (r=0.11,
p=0.19), and there was little trend toward increasing median
CRP levels (p=0.28).
Prevalence of elevated CRP levels in patients with disease
activity assessed by CDAI
Only 7 patients were in remission by CDAI, and, of these, 4 had
CRP levels.3 mg/L (Figure 3). Of the 51 RA patients with mild
disease activity by CDAI, 67% had CRP levels.3 mg/L, and the
median CRP level in this group was 5.3 mg/L (Figure 3; Table 2).
The prevalence of CRP.3 mg/dl was the same in those with
moderate disease by CDAI (67%), and the median CRP was
Figure 2. CRP Levels by (a) Swollen and (b) Tender Joint Count Category. CRP (log2) values are shown within each swollen joint count
category. CRP levels and joint counts were determined at the same clinic visit. Blue lines denote location of the median. The dotted reference line is at
CRP=3 mg/L.
doi:10.1371/journal.pone.0006242.g002
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statistically significant positive correlation with CRP (r=0.18,
p=0.027; Figure 3).
CRP levels in patients with disease activity assessed by
DAS28
In our cohort of patients, those classified by DAS28-ESR as in
remission or with mildly active disease had median CRP levels of
2.8 and 2.9 mg/L, respectively - lower than the levels of CRP
found in patients similarly classified by CDAI (Figure 4a).
However, a substantial percentage of patients in remission or
with mildly active disease by DAS28-ESR (50% and 47%
respectively) still had CRP levels.3 mg/L (Figure 4a; Table 2).
Of those with moderate disease activity by DAS28-ESR (n=78),
73% had CRP levels.3 mg/L (Figure 4a; Table 2). When the
DAS28-CRP was used instead to classify disease activity, more
patients were categorized as having remission or mild disease; 42%
of patients in remission, 84% of patients with mild activity, and
70% of those with moderate activity had CRP levels.3 mg/L
(Figure 4b; Table 2).
Prevalence of CRP levels associated with very high
cardiovascular risk
Overall, 25% of our RA patients had CRP levels.10 mg/L
(Table 1). Of patients thought to have well-controlled disease by
their physicians (physician global assessment scores,30) or by
themselves (patient global assessment scores,30), 15% and 20%,
respectively, had CRP.10 mg/L (Figure 1). When disease was
assessed by joint counts, 21% of patients with 0 swollen joints had
CRP.10 mg/L, as did 29% of patients with 1 swollen joint
(Figure 2a). Similarly, 16% of patients with no tender joints and
30% with 1 tender joint had CRP.10 mg/L (Figure 2b).
Among patients who met criteria for remission, the prevalence of
CRP.10 mg/L ranged for 0% for CDAI to 5% for DAS28-ESR
and DAS28-CRP (Table 2). However, a substantial proportion of
patients with mild disease activity by CDAI (16%), DAS28-ESR
(16%), or DAS28-CRP (19%) had CRP levels.10 mg/L (Table 2).
The percentages were higher still in those with moderate disease
activity by these measures: 25–33% (Table 2).
Discussion
Our data demonstrate that a substantial proportion of RA
patients thought to have suppressed disease nonetheless have CRP
levels that are associated with high (.3 mg/L) and very high
(.10 mg/L) risk of cardiovascular events in the general population.
Our findings should be viewed in the context of currently
Figure 3. CRP Levels by Disease Activity as Determined by
CDAI. CRP (log2) values are shown within each CDAI category. CRP
levels and CDAI were determined at the same clinic visit. Blue lines
denote location of median. The dotted reference line is at CRP=3 mg/L.
doi:10.1371/journal.pone.0006242.g003
Table 2. Prevalence of CRP.3 mg/L and.10 mg/L in
patients categorized by level of disease activity.
CRP Level Measure Remission Mild Moderate Severe P-value
CRP.3 CDAI 57% 67% 67% 75% 0.36
DAS28-ESR 50% 47% 73% 79% 0.0046
DAS28-CRP 42% 84% 70% 93% 0.0011
CRP.10 CDAI 0% 16% 25% 36% 0.0091
DAS28-ESR 5% 16% 26% 38% 0.0038
DAS28-CRP 5% 19% 33% 47% 0.0001
doi:10.1371/journal.pone.0006242.t002
Figure 4. CRP Levels by Disease Activity as determined by (a)
DAS28-ESR and (b) DAS28-CRP. CRP (log2) values are shown within
each swollen joint count category. CRP levels and DAS28 were
determined at the same clinic visit. Blue lines denote location of
median. Dotted reference line is at CRP=3 mg/L.
doi:10.1371/journal.pone.0006242.g004
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American College of Rheumatology (ACR) recommends a
therapeutic goal of remission or mild disease activity by CDAI or
DAS28 [32]. In our study, 47% to 83% of those with mild activity
by these measures had CRP levels.3 mg/L, and 16% to 19% had
CRP levels.10 mg/L. In its guidance on the use of TNF inhibitors
for RA, the United Kingdom’s National Institute for Health and
Clinical Excellence accepts moderate disease activity and requires
severe activity by DAS28 for the introduction of TNF inhibitors
[33]. We observed that 70% to 73% of our patients with moderate
disease activity by DAS28 criteria had CRP levels.3 mg/L and
that 26% to 33% of these had CRP levels.10 mg/L.
The basis for the high prevalence of elevated CRP levels in RA
patients with mild to moderate disease activity is not certain but
likely is multifactorial. First, the clinical joint exam lacks sensitivity
to detect subtle synovitis and may underestimate the extent of active
rheumatoiddisease.Indeed,magneticresonanceimagingcandetect
inflammation in rheumatoid joints clinically thought to be free of
synovitis [34]. Second, chronic inflammation at extraarticular sites
(e.g., gingivitis) might stimulate CRP production. None of our
patients had clinically apparent infections at the time of analysis,
and CRP levels in our patients with mild disease activity are stable
over time (unpublished observations), arguing against an intercur-
rentevent as a source of elevated CRP. Third, the low prevalence of
smoking in the SFGH RA cohort (12.5%) excludes an important
contribution of smoking to CRP levels in our study. Finally, adipose
tissue, particularly visceral fat, is a source of CRP production and
can make contributions to the serum CRP levels of RA patients
independent of their disease activity [35].
Several studies suggest that treatment of RA with methotrexate
or TNF inhibitors may reduce cardiovascular events and mortality
due to CVD [36–39], but the improvement may only occur in
those who have a response to therapy [39].
The great majority of patients with moderate disease activity or
better in our study were on methotrexate or other synthetic
disease-modifying anti-rheumatic drugs. Among the patients
receiving TNF inhibitors in our study, the median CRP level
(6.0 mg/L) and the prevalence of CRP.3 mg/L (76%)
or.10 mg/L (27% ) did not differ significantly from those of
patients not using TNF inhibitors, but the patients receiving these
agents appeared to have more severe disease (data not shown).
While therapies may reduce some of the overall cardiovascular
risk of a population of RA patients, there are limited data on the
extent of residual cardiovascular risk in individual treated RA
patients. For example, it remains to be seen whether treating RA
patients to levels of mild disease activity or remission, as assessed by
the best available clinical metrics, normalizes cardiovascular risk
relative to that of the general population. However, our finding that
a majority of patients who achieve these ACR-recommended
targets nonetheless have elevated CRP levels suggests that excess
cardiovascular risk persists. Consistent with this possibility,
endothelial dysfunction was reported in a study of young to middle
aged patients with RA who were in remission or had mild disease
activity by DAS28-ESR and who were free from other cardiovas-
cular risk factors. In that study, endothelial dysfunction correlated
with average CRP levels and disease duration [10].
Our study has several limitations. First, it is cross-sectional.
However, studies demonstrating CRP to be an independent
predictor of cardiovascular risk, including those involving RA
patients, often used a single, baseline measurement of CRP [9,17–
19,23]. Second, we examine a biomarker for cardiovascular risk
(CRP) rather than cardiovascular outcomes. Levels of cardiovas-
cular risk have not been assigned to specific values of CRP in RA,
as has been done in the general population. However, the
available evidence, although limited in scope, does not support the
notion of differential cardiovascular risk for a given level of CRP
between the general population and patients with RA. For
example, in a 10 year observational study of newly diagnosed RA,
patients whose baseline CRP levels were$5 mg/L had a hazard
ratio of death from CVD of 14.7 (95% CI 2.0–109.2) relative to
those with baseline CRP levels,4 mg/L [9]. Moreover, RA
patients with even modestly elevated CRP levels (.1.92 mg/L)
are more insulin-resistant than those with lower CRP levels [40].
Inflammation-induced insulin resistance contributes to the delete-
rious effects of inflammation on the cardiovascular system [41].
Our study indicates that systemic inflammation, as reflected in
an elevated CRP, persists in a sizable number of RA patients with
minimal or no clinically detectable joint disease and thus may
confer increased cardiovascular risk upon these patients. Future
studies should examine the relation of subclinical joint inflamma-
tion detected by sensitive imaging techniques to markers of
cardiovascular risk. If this risk predicted here is confirmed by
future studies, then recognition of these at-risk RA patients may
have important implications for therapy. One option might be to
base treatment decisions on disease assessment scores more heavily
weighted towards markers of inflammation or to treat subclinical
joint inflammation. Given the efficacy, toxicity, and expense of
current RA therapies, however, an alternative strategy might be to
aggressively modify traditional cardiovascular risk factors in those
with persistent systemic inflammation. Even in the absence of
elevated low density lipoprotein, the use of statins might reduce
cardiovascular risk in RA patients with elevated CRP. Of note in
this regard, the recently published JUPITER trial of apparently
healthy individuals without hyperlipidemia but with CRP$2 mg/
L demonstrated that statin therapy significantly reduced major
cardiovascular events, with a hazard reduction of 0.56
(p,0.00001) [42]. With respect to RA, our results point to the
need to define the extent to which the persistent systemic
inflammation places individual RA patients at risk for CVD and
to determine the cardiovascular benefits of more aggressive RA
therapy, of risk modification, and of the use of statins.
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